Value of KRAS as prognostic or predictive marker in NSCLC: Results from the TAILOR trial

Annals of Oncology

Volumn 26, Issue 10, 2015, Pages 2079-2084

  Rulli, E ^a   Marabese, M ^a   Torri, V ^a   Farina, G ^b   Veronese, S ^c   Bettini, A ^d   Longo, F ^e   Moscetti, L ^f   Ganzinelli, M ^g   Lauricella, C ^c   Copreni, E ^a   Labianca, R ^d   Martelli, O ^h   Marsoni, S ⁱ   Broggini, Massimo ^a   Garassino, M C ^g  

^a Laboratorio per la Ricerca Clinica Oncologica   (United States)

^b Department of Medical Oncology Fatebenefratelli e Oftalmico Hospital   (United States)

^c Ospedale Niguarda C Granda   (United States)

^d PAPA GIOVANNI XXIII HOSPITAL   (Italy)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

^f BELCOLLE HOSPITAL   (Italy)

^g NATIONAL CANCER INSTITUTE   (Italy)

^h Hospital San Giovanni Addolorata   (Italy)

ⁱ CANDIOLO CANCER INSTITUTE   (Italy)

Author keywords

Docetaxel; Erlotinib; KRAS; NSCLC

Indexed keywords

DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; K RAS PROTEIN; PLATINUM DERIVATIVE; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; KRAS PROTEIN, HUMAN; PROTEIN P21; TAXOID; TUMOR MARKER;

ADVANCED CANCER; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; FEMALE; GENE EXPRESSION; GENE MUTATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; ADENOCARCINOMA; CANCER STAGING; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CLINICAL TRIAL; FOLLOW UP; GENETICS; LUNG NEOPLASMS; MORTALITY; MUTATION; PATHOLOGY; PROGNOSIS; SURVIVAL RATE;

ADENOCARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; ERLOTINIB HYDROCHLORIDE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MUTATION; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS P21(RAS); RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL RATE; TAXOIDS;

EID: 84943765451     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdv318     Document Type: Article

References (26)

1. Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D. RAS oncogenes: weaving a tumorigenic web. Nat Rev Cancer 2011; 11: 761-774.
2. Karachaliou N, Mayo C, Costa C et al. KRAS mutations in lung cancer. Clin Lung Cancer 2013; 14: 205-214.
3. Piva S, Ganzinelli M, Garassino MC et al. Across the universe of k-ras mutations in non-small-cell-lung cancer. Curr Pharm Des 2014; 20: 3933-3943.
4. Martin P, Leighl NB, Tsao MS, Shepherd FA. KRAS mutations as prognostic and predictive markers in non-small cell lung cancer. J Thorac Oncol 2013; 8:530-542.
5. Shepherd FA, Domerg C, Hainaut P et al. Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in earlystage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy. J Clin Oncol 2013; 31: 2173-2181.
6. Mascaux C, Iannino N, Martin B et al. The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer 2005; 92: 131-139.
7. Linardou H, Dahabreh IJ, Kanaloupiti D et al. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol 2008; 9: 962-972.
8. Mao C, Qiu L-X, Liao R-Y et al. KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta-analysis of 22 studies. Lung Cancer 2010; 69: 272-278.
9. Garassino MC, Marabese M, Rusconi P et al. Different types of K-Ras mutations could affect drug sensitivity and tumour behaviour in non-small-cell lung cancer. Ann Oncol 2011; 22: 235-237.
10. Stinchcombe TE, Der CJ. Are all KRAS mutations created equal? Lancet Oncol 2011; 12: 717-718.
11. Garassino MC, Marsoni S, Floriani I. Testing epidermal growth factor receptor mutations in patients with non-small-cell lung cancer to choose chemotherapy:the other side of the coin. J Clin Oncol 2011; 29: 3835-3837; author reply 3837-3839.
12. Farina G, Longo F, Martelli O et al. Rationale for treatment and study design of tailor: a randomized phase III trial of second-line erlotinib versus docetaxel in the treatment of patients affected by advanced non-small-cell lung cancer with the absence of epidermal growth factor receptor mutations. Clin Lung Cancer 2011; 12: 138-141.
13. Garassino MC, Martelli O, Broggini M et al. Erlotinib versus docetaxel as secondline treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. Lancet Oncol 2013; 14:981-988.
14. Keedy VL, Temin S, Somerfield MR et al. American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J Clin Oncol 2011; 29: 2121-2127.
15. Eberhard DA, Johnson BE, Amler LC et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005; 23: 5900-5909.
16. Douillard JY, Shepherd FA, Hirsh V et al. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer:data from the randomized phase III INTEREST trial. J Clin Oncol 2010; 28:744-752.
17. Kim ES, Hirsh V, Mok T et al. Gefitinib versus docetaxel in previously treated nonsmall- cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008; 372:1809-1818.
18. The Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature 2014; 511: 543-550.
19. Chen Z, Fillmore CM, Hammerman PS et al. Non-small-cell lung cancers: a heterogeneous set of diseases. Nat Rev Cancer 2014; 14: 535-546.
20. Karapetis CS, Khambata-Ford S, Jonker DJ et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359:1757-1765.
21. Kawaguchi T, Ando M, Asami K et al. Randomized phase III trial of erlotinib versus docetaxel as second- or third-line therapy in patients with advanced non-small-cell lung cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA). J Clin Oncol 2014; 32: 1902-1908.
22. Gregorc V, Novello S, Lazzari C et al. Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial. Lancet Oncol 2014; 15: 713-721.
23. Johnson DH, Schiller JH, Bunn PA, Jr. Recent clinical advances in lung cancer management. J Clin Oncol 2014; 32: 973-982.
24. Stinchcombe TE, Johnson GL. MEK inhibition in non-small cell lung cancer. Lung Cancer 2014; 86: 121-125.
25. Ostrem JM, Peters U, Sos ML et al. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 2013; 503: 548-551.
26. Brunelli L, Caiola E, Marabese M et al. Capturing the metabolomic diversity of KRAS mutants in non-small-cell lung cancer cells. Oncotarget 2014; 5:4722-4731.